Research Article

Association between Sleep Disruption and Levels of Lipids in Caucasians with Type 2 Diabetes

Table 1

Baseline characteristics based on sleep quality.

GQ ( )PQ ( )Sig

Female20 (31.7)32 (62.7)0.002
Antihypertensive45 (71.4)43 (84.3)0.16
Lipid lowering30 (47.6)22 (43.1)0.773
Oral antidiabetic 41 (66.1)34 (65.4)1.0
Insulin14 (22.6)8 (15.4)0.522
Diet controlled13 (21)8 (15.4)0.664
Age (years)64.0 ± 11.3266.0 ± 10.980.339
Weight (kg)86.63 ± 21.6583.25 ± 16.260.358
BMI (kg/m2)30.59 ± 7.330.84 ± 4.360.835
SBP (mmHg)137.30 ± 18.75147.16 ± 17.670.005
DBP (mmHg)76.43 ± 12.2680.04 ± 10.350.097
Glucose (mmol/L)7.2 (5.9–8.5)7.3 (6.7–9.4)0.169
HbA1c
 (%)6.1 (5.5–7.2)6.8 (6.2–7.6)0.026
 mmol/mol43.2 (36.6–55.2)50.8 (44.3–59.6)
UAC (mg/mmol)8.11 (3.12–33.1)18.02 (8.19–44.27)0.03
Total cholesterol (mmol/L)4.50 ± 0.874.87 ± 0.870.025
TG (mmol/L)1.38 (0.97–2.07)1.69 (1.26–2.44)0.026
HDL (mmol/L)1.21 ± 0.291.28 ± 0.340.249
LDL (mmol/L)2.51 ± 0.622.73 ± 0.720.097
Sleep duration (h)7.25 ± 0.955.57 ± 1.49<0.001

SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; HbA1c: glycated haemoglobin; UAC: urinary albumin : creatinine ratio; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein. Genders, treatment with antihypertensive, lipid-lowering agents, oral antidiabetic medications, insulin, and diet controlled are expressed in (%).